What patient factors do you feel are most important when considering reduced dosing regimens of IL17a inhibitors such as secukinumab and ixekizumab for psoriasis?

How do you go about implementing this change and how do you counsel the patient on risks vs benefits?

Answer from: at Academic Institution

If the psoriasis is completely clear, the patient may wonder if they need to continue treatment. If they want to spread out the doses to see how little they need, I usually have no objection.

Please select the option that best describes you:

What patient factors do you feel are most important when considering reduced dosing regimens of IL17a inhibitors such as secukinumab and ixekizumab for psoriasis?

Related Questions